Charles Schwab Investment Management Inc. Boosts Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Charles Schwab Investment Management Inc. increased its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 19.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 430,665 shares of the company's stock after buying an additional 68,860 shares during the period. Charles Schwab Investment Management Inc. owned about 0.68% of Vera Therapeutics worth $18,213,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. SG Americas Securities LLC increased its stake in shares of Vera Therapeutics by 116.7% during the fourth quarter. SG Americas Securities LLC now owns 20,270 shares of the company's stock worth $857,000 after buying an additional 10,916 shares during the period. Lord Abbett & CO. LLC increased its stake in Vera Therapeutics by 41.1% in the third quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company's stock valued at $18,830,000 after purchasing an additional 124,197 shares during the last quarter. Barclays PLC increased its stake in Vera Therapeutics by 94.1% in the third quarter. Barclays PLC now owns 85,395 shares of the company's stock valued at $3,774,000 after purchasing an additional 41,394 shares during the last quarter. Geode Capital Management LLC increased its stake in Vera Therapeutics by 2.1% in the third quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company's stock valued at $44,415,000 after purchasing an additional 20,223 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in Vera Therapeutics in the third quarter valued at approximately $475,000. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Vera Therapeutics Price Performance

Shares of NASDAQ:VERA traded down $0.62 during midday trading on Friday, hitting $27.08. 1,141,126 shares of the stock were exchanged, compared to its average volume of 730,880. The company has a 50 day moving average price of $31.65 and a 200-day moving average price of $39.27. Vera Therapeutics, Inc. has a twelve month low of $25.99 and a twelve month high of $51.61. The stock has a market cap of $1.73 billion, a P/E ratio of -10.38 and a beta of 1.17. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.11. On average, research analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on VERA. Guggenheim increased their price objective on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th. JPMorgan Chase & Co. lowered their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 4th. Wolfe Research started coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 target price on the stock. Finally, The Goldman Sachs Group started coverage on shares of Vera Therapeutics in a research report on Tuesday, January 28th. They set a "buy" rating and a $58.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Vera Therapeutics has a consensus rating of "Buy" and a consensus target price of $64.67.

Insider Activity at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total value of $730,450.00. Following the completion of the sale, the chief executive officer now owns 143,603 shares in the company, valued at $5,993,989.22. The trade was a 10.86 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 21.70% of the stock is currently owned by corporate insiders.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.